Fintech

ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC

Globenewswire·March 27, 2026 at 12:30 PM

Company to host a conference call and webcast on Tuesday, March 31, 2026 at 4:30 pm ET...

Original Source

Related in Fintech